Boyd A E, Aguilar-Bryan L, Nelson D A
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030.
Am J Med. 1990 Aug 20;89(2A):3S-10S; discussion 51S-53S. doi: 10.1016/0002-9343(90)90330-g.
A high-affinity sulfonylurea receptor has been identified on the plasma membrane of the beta cell. The potent second-generation sulfonylureas, glyburide and glipizide, saturate the receptor in the low nM concentration range, whereas first-generation drugs bind to and saturate the receptor in the microM range. For each of the sulfonylureas, there is excellent quantitative agreement among the equilibrium binding constant (Kd), the half-maximal inhibition of potassium ion (K+) efflux (K0.5), and the half-maximal stimulation of insulin secretion (ED50), when these values are obtained from insulin-secreting cell lines or from isolated mouse pancreatic islets. The inhibition of K+ efflux by the sulfonylureas, coupled with the sulfonylurea inhibition of the activity of a specific adenosine triphosphate (ATP)-sensitive K+ channel embedded in the plasma membrane of whole cells or in excised membrane patches, suggests that the sulfonylurea receptor is this channel protein or a closely associated subunit. The activity of the ATP-sensitive K+ channel is also controlled by the insulin secretagogues, glucose and certain amino acids. These compounds must be metabolized to inhibit the channel activity and appear to do so by increasing the level of ATP or by increasing the ATP/adenosine diphosphate (ADP) ratio. ATP reduces channel activity by binding to a specific nucleotide-binding site on the cytoplasmic surface of the protein. There is a synergy between the action of glucose and that of the sulfonylureas. The sulfonylureas, for example, are better effectors of insulin secretion in the presence of glucose. Inhibition of the ATP-sensitive K+ channels results in depolarization of the plasma membrane and a subsequent influx of extracellular calcium ions through voltage-dependent calcium channels. An increase in the free intracellular calcium level is the signal, or "second messenger," that triggers exocytosis and the release of insulin. The sulfonylurea receptor has a molecular weight of 140,000 and can be solubilized by digitonin, retaining the same rank order of sulfonylurea binding affinities as the membrane-bound protein. Several laboratories are currently purifying the receptor and/or cloning the receptor gene.
在β细胞的质膜上已鉴定出一种高亲和力的磺脲类受体。强效的第二代磺脲类药物格列本脲和格列吡嗪在低纳摩尔浓度范围内就能使该受体饱和,而第一代药物则在微摩尔范围内与受体结合并使其饱和。对于每种磺脲类药物,当从胰岛素分泌细胞系或分离的小鼠胰岛中获得平衡结合常数(Kd)、钾离子(K+)外流的半数最大抑制浓度(K0.5)以及胰岛素分泌的半数最大刺激浓度(ED50)时,这些数值之间存在极好的定量一致性。磺脲类药物对K+外流的抑制作用,以及磺脲类药物对嵌入全细胞质膜或切除膜片上的特定三磷酸腺苷(ATP)敏感性钾通道活性的抑制作用,表明磺脲类受体就是这种通道蛋白或与之紧密相关的亚基。ATP敏感性钾通道的活性也受胰岛素促分泌剂、葡萄糖和某些氨基酸的调控。这些化合物必须经过代谢才能抑制通道活性,而且似乎是通过提高ATP水平或提高ATP/二磷酸腺苷(ADP)比值来实现的。ATP通过与该蛋白细胞质表面的一个特定核苷酸结合位点结合来降低通道活性。葡萄糖和磺脲类药物的作用之间存在协同效应。例如,在有葡萄糖存在的情况下,磺脲类药物是更好的胰岛素分泌效应剂。对ATP敏感性钾通道的抑制导致质膜去极化,随后细胞外钙离子通过电压依赖性钙通道内流。细胞内游离钙水平的升高是触发胞吐作用和胰岛素释放的信号,即“第二信使”。磺脲类受体的分子量为140,000,可用洋地黄皂苷使其溶解,其保留的磺脲类结合亲和力顺序与膜结合蛋白相同。目前有几个实验室正在纯化该受体和/或克隆受体基因。